Search Results
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
including: Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
including: Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You
More news about: AbbVie
Jun 02, 2026, 09:00 ET As 47-Day Certificate Cycles Loom, Encryption Consulting Teams with F5 to Deliver Zero-Touch Certificate Lifecycle Management
F5 BIG-IP environments on the F5 ADSP, arriving at a critical moment as the industry moves toward mandatory 47-day TLS certificate lifespans.
More news about: Encryption Consulting LLC
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Permanently discontinue Retevmo for recurrent hypersensitivity.Tumor lysis syndrome (TLS) occurred in 0.6% of patients with medullary thyroid carcinoma receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration.
More news about: Eli Lilly and Company
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
UseTumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
UseTumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management
More news about: AbbVie
May 27, 2026, 09:35 ET San Diego Native Kris Lichter Named CEO of TL Foundation to Accelerate Local Innovation and Build Lasting Economic Strength
TL's nonprofit venture model transforms philanthropic capital into local investment and a permanent funding engine for San DiegoSAN DIEGO, May 27, 2026 /PRNewswire/ -- TL Foundation, San
More news about: TL Foundation
May 26, 2026, 09:11 ET NIAGARA NETWORKS LAUNCHES EPACKETRON: A 600 Gbps NETWORK INTELLIGENCE PLATFORM TRANSFORMING SOC AND NOC VISIBILITY
massive traffic volumes required for effective detection and analytics. Security platforms are often forced to perform compute-intensive tasks such as TLS decryption, deduplication, header stripping, and flow analysis, reducing their ability to focus on threat detection.ePacketron addresses
More news about: Niagara Networks Inc
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
patients with severe or life-threatening hemorrhage.Tumor Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary thyroid carcinoma receiving GAVRETO. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration.
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:00 ET Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
quantification and spatial tumor microenvironment (TME) analysis. Using AI to characterize HER2 expression, immune phenotypes, tertiary lymphoid structures (TLS), tumor-infiltrating lymphocytes (TILs), and endothelial cells, the studies highlight the potential of integrated biomarker analysis to improve precision
More news about: Lunit
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Permanently discontinue Retevmo for recurrent hypersensitivity.Tumor lysis syndrome (TLS) occurred in 0.6% of patients with medullary thyroid carcinoma receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration.
More news about: Eli Lilly and Company
May 19, 2026, 13:45 ET InventHelp Inventor Develops New Key Storage Accessory (TLS-1345)
Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1345, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 13:30 ET InventHelp Inventor Develops Improved Concrete Design (TLS-1340)
Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1340, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 13:15 ET InventHelp Inventor Develops Newly Designed Propane Grill (TLS-1328)
Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1328, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 13:00 ET InventHelp Inventor Develops Scented Lawn & Garden Product (TLS-1327)
Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1327, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 13:00 ET Valkey Enhances Efficiency, Security, and Modular Performance with 9.1 Release and New Ecosystem Integrations
directly reduces cloud infrastructure spend.The release also tightens security without adding operational complexity. Valkey 9.1 includes automated TLS certificate reloading and a new database-level ACL system, providing fine-grained multi-tenant isolation within a single instance. These changes take
More news about: Valkey
May 19, 2026, 12:45 ET InventHelp Inventor Develops New Bandage Dispenser (TLS-1305)
National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1305, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 12:30 ET InventHelp Inventor Develops New Toilet Bowl Cleaning Tool (TLS-1069)
Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1069, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 19, 2026, 09:00 ET With 200-Day Certificate Limits Now in Effect, Encryption Consulting Releases CertSecure Manager v3.3 with Zero-Touch Renewal for Every Major Enterprise Platform
PROSPER, Texas, May 19, 2026 /PRNewswire/ -- With just 200 days to renew public TLS certificates, down from 398 and soon to be 47, enterprises face increasing pressure to renew. Encryption Consulting has responded by releasing CertSecure
More news about: Encryption Consulting LLC
May 18, 2026, 12:15 ET Verification by Default: SCRT Labs Integrates Intel® Trust Authority Into Every SecretVM
verification path.Tokens are bound to the TLS connection. The report_data field of each attestation token carries the fingerprint of the SecretVM's TLS certificate. A relying party that fetches a token over TLS and checks the binding has strong assurance that the
More news about: Secret Network Foundation
May 18, 2026, 08:11 ET WinMagic Responds to New CISA OT Guidance With Transport-Layer Identity Architecture
like SAML or OIDC.Transport-layer identity assurance: Live Identity in Transaction embeds identity directly into the TLS handshake through mutual TLS, reducing reliance on bearer tokens and minimizing session hijacking risk."MagicEndpoint was architected for exactly the constraints
More news about: WInMagic
May 14, 2026, 09:55 ET Verkada achieves FedRAMP Moderate Authorization
FedRAMP marketplace and accessible through major government procurement channels, including Carahsoft's GSA Schedule, NASA SEWP V, ITES-SW2, DLA TLS, and various Socio Economic partner vehicles.Learn more about Verkada's government-grade solutions
More news about: Verkada
May 06, 2026, 22:00 ET NEXCOM Delivers Optimized Edge Security for Post-Quantum Workloads
current and PQC encryption workloads:Up to 3.5K connections per second per core with PQC algorithmsUp to 2.1x higher TLS throughput in hybrid deploymentsUp to 2x performance improvement with traditional cryptographyNEXCOM
More news about: NEXCOM International Co., Ltd.
May 06, 2026, 22:00 ET NEXCOM Delivers Optimized Edge Security for Post-Quantum Workloads
current and PQC encryption workloads:Up to 3.5K connections per second per core with PQC algorithmsUp to 2.1x higher TLS throughput in hybrid deploymentsUp to 2x performance improvement with traditional cryptographyNEXCOM
More news about: NEXCOM International Co., Ltd.
May 05, 2026, 06:30 ET VIAVI Launches CyberFlood CF1000 Appliance for Next-Generation Validation of Multi-Terabit Security and AI Infrastructure
networks and emerging quantum-era threats, the platform provides industry‑leading Transport Layer Security (TLS) performance, supporting more than 500Gbps of encrypted throughput and up to 800,000 TLS v1.3 connections per second. In addition, CF1000 extends CyberFlood's capabilities with highly scalable
More news about: VIAVI Solutions